Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

By S. Pearson, R. Troughton, A. Richards. New England Journal of Medicine, 2011

4,081 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/9afdbd859548c6b34b0c6fcfae6384653640a1ac

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. (2018, neutral): “14 Low dose rivaroxaban prevents venous thromboembolism after orthopaedic surgery, 15 and the Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-2) trial 16 showed that low-dose rivaroxaban (2·5 mg twice a day) used in addition to dual antiplatelet therapy reduced major adverse…”
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “77) compared to warfarin [123, 124, 128].”
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, neutral): “been associated with adverse prognosis (195, 196).”
Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. (2014, background): “Siegel, Ashok Garg (Advanced Cardiac Specialists, Gilbert, Arizona [20]); Gregory Mishkel (PERC/St John’s Hospital, Springfield, Illinois [17]); Stephen Ramee (Ochsner Clinic, New Orleans, Louisiana [14]); Saibal Kar (Cedars-Sinai Medical Center, Los Angeles, California [16]); Brijeshwar Maini (Moff”
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design (2012, methodology): “A 1- to 7-day Holter monitor is an effective way to identify frequent asymptomatic recurrences of AF [111, 325, 392, 455].”
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. (2014, background): “in AF excluded patients with mechanical and bioprosthetic heart valves.(426,430,432,433) A recent trial of dabigatran compared”